Radio-frequency identification (RFID) tag localisation of non-palpable breast lesions a single centre experience
The purpose of this study is to report the surgical experience and outcomes with pre-operative localisation of non-palpable breast lesions using the RFID tag system. The cohort for this prospective study included patients over the age of 18 with biopsy proven, non-palpable indeterminate lesions, DCI...
Gespeichert in:
Veröffentlicht in: | Breast (Edinburgh) 2023-06, Vol.69, p.417-421 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The purpose of this study is to report the surgical experience and outcomes with pre-operative localisation of non-palpable breast lesions using the RFID tag system.
The cohort for this prospective study included patients over the age of 18 with biopsy proven, non-palpable indeterminate lesions, DCIS or breast cancer requiring pre-operative localisation before surgical excision between September 2020 and July 2022.
A total of 312 RFID tags were placed in 299 consecutive patients. Indications for localisation included non-palpable invasive cancer in 255 (85.3%) patients, in situ disease in 38 (12.7%) and indeterminate lesions requiring surgical excision in 6 (2.0%). Both in situ and invasive lesions had a median size of 13 mm (range 4–100 mm) on pre-operative imaging. The RFID tags were in situ for a median time of 21 days before surgery (range 0–233 days). Of the 213 tags, 292 (93.6%) were introduced using ultrasound (USS) guidance and stereotactically in 20 (6.4%). In 3 (1.0%) cases the RFID tag was either not satisfactorily deployed at the intended target or retrieved intra-operatively. Following discussion of post-operative histology by the multi-disciplinary team, further surgery for close or involved margins was for 26 (8.7%) patients.
The Hologic RFID tag system can be used for accurate pre-operative localisation of non-palpable masses as well as diffuse abnormalities such as mammographic distortions and calcifications. It has advantages of flexibility for scheduling image-guided insertion independently of scheduled operating lists and can be placed to localise lesions prior to initiating neoadjuvant systemic treatment.
•RFID tag localisation of non-palpable malignant and indeterminate lesions is accurate and oncologically safe.•Insertion by ultrasound or sterotactic guidance uses visible tumour, calcification or a hydroclip as the target.•In 99% of cases the RFID tag was satisfactorily deployed at the intended target and retrieved intra-operatively.•The rate of re-operation for close or involved margins was 8.6%. |
---|---|
ISSN: | 0960-9776 1532-3080 |
DOI: | 10.1016/j.breast.2023.04.005 |